A comparison of the genetic activity of pyrvinium pamoate with that of several other anthelmintic drugs in Saccharomyces cerevisiae.
Several anthelmintic drugs that are used routinely in oxyuriasis therapy were analyzed for genotoxicity in a diploid mitotic recombination and gene conversion assay (strain D5 of Saccharomyces cerevisiae), and in a haploid yeast reversion assay (strain XV185-14C). Piperazine citrate, piperazine adipate, mebendazole and thiabendazole did not appear to be genotoxic in either yeast strain. Pyrvinium pamoate induced the reversion of the missense, nonsense and frameshift alleles in strain XV185-14C, whereas pyrantel pamoate induced only the reversion of the frameshift allele. Pyrvinium pamoate was recombinogenic in strain D5, and there is an indication that pyrantel pamoate, at the lowest dose that was tested, might induce gene conversion or aneuploidy.
D000871:Anthelmintics / Q000633:toxicity*; D002453:Cell Cycle; D005785:Gene Conversion / Q000187:drug effects; D008463:Mebendazole / Q000633:toxicity; D008938:Mitosis / Q000187:drug effects; D009152:Mutagenicity Tests; D000077489:Piperazine; D010879:Piperazines / Q000633:toxicity; D011716:Pyrantel Pamoate / Q000633:toxicity; D011774:Pyrvinium Compounds / Q000633:toxicity*; D011995:Recombination, Genetic / Q000187:drug effects; D012441:Saccharomyces cerevisiae / Q000187:drug effects; D013827:Thiabendazole / Q000633:toxicity; D013997:Time Factors
D000871:Anthelmintics; D010879:Piperazines; D011774:Pyrvinium Compounds; D000077489:Piperazine; C024631:pyrvinium; D011716:Pyrantel Pamoate; D008463:Mebendazole; D013827:Thiabendazole